IGMS - IGM Biosciences GAAP EPS of -$1.33 misses by $0.93 revenue of $0.4M
- IGM Biosciences press release ( NASDAQ: IGMS ): Q2 GAAP EPS of -$1.33 misses by $0.93 .
- Revenue of $0.4M.
- Cash and investments as of June 30, 2022 were $513.2 million, compared to $229.5 million as of December 31, 2021.
- IGM expects to end 2022 with a balance of approximately $400 million in cash and investments. IGM estimates full year collaboration revenue of approximately $1 million related to the Sanofi agreement. IGM reiterates its previously issued financial guidance expecting full year GAAP operating expenses of $250 million to $260 million including estimated non-cash stock-based compensation expense of approximately $50 million.
- Shares -1.78% .
For further details see:
IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M